复星医药
(600196)
| 流通市值：535.98亿 | | | 总市值：675.62亿 |
| 流通股本：21.18亿 | | | 总股本：26.70亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,073,223,477.03 | 41,661,612,748.15 | 29,393,385,360.91 | 19,514,431,849.59 |
| 营业收入 | 10,073,223,477.03 | 41,661,612,748.15 | 29,393,385,360.91 | 19,514,431,849.59 |
| 二、营业总成本 | 9,532,295,160.5 | 40,087,325,053.49 | 28,415,595,587.6 | 18,904,362,502.04 |
| 营业成本 | 5,066,739,286.46 | 20,800,103,192.22 | 15,225,462,362.51 | 10,123,465,094.36 |
| 税金及附加 | 74,610,767.33 | 344,617,180.44 | 240,949,647.3 | 184,748,211.66 |
| 销售费用 | 2,254,592,699.25 | 9,193,022,306.29 | 6,269,283,998.05 | 4,211,062,971.76 |
| 管理费用 | 1,017,224,018.98 | 4,583,601,754.23 | 3,067,356,397.76 | 2,028,108,812.5 |
| 研发费用 | 896,787,372.5 | 4,012,555,580.82 | 2,729,517,164.8 | 1,716,662,245.02 |
| 财务费用 | 222,341,015.98 | 1,153,425,039.49 | 883,026,017.18 | 640,315,166.74 |
| 其中:利息费用 | 296,510,967.36 | 1,265,350,720.93 | 974,025,974.09 | 652,778,681.56 |
| 其中:利息收入 | 72,141,643.38 | 300,503,664.21 | 236,793,412.05 | 163,453,169.49 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 160,915,938.1 | -322,268,457.29 | -375,106,548.93 | -48,596,693.14 |
| 加:投资收益 | 617,532,169.82 | 3,763,778,024.02 | 3,095,360,303.24 | 2,120,176,697.39 |
| 资产处置收益 | 1,371,616.94 | 69,350,406.88 | 62,764,603.19 | 2,116,774.07 |
| 资产减值损失(新) | 4,113,842.22 | -150,063,042.97 | -84,326,905.63 | -64,269,906.34 |
| 信用减值损失(新) | -5,056,060.11 | -125,174,547.55 | -47,122,378.6 | -28,733,602.79 |
| 其他收益 | 55,570,376.53 | 418,441,261.84 | 277,406,532.99 | 170,445,774.12 |
| 四、营业利润 | 1,375,376,200.03 | 5,228,351,339.59 | 3,906,765,379.57 | 2,761,208,390.86 |
| 加:营业外收入 | 7,059,726.87 | 46,772,747.6 | 17,991,026.97 | 10,544,031.33 |
| 减:营业外支出 | 24,891,490.73 | 163,140,823.32 | 87,412,924.75 | 53,270,839.11 |
| 五、利润总额 | 1,357,544,436.17 | 5,111,983,263.87 | 3,837,343,481.79 | 2,718,481,583.08 |
| 减:所得税费用 | 277,916,582.03 | 864,053,635.49 | 781,251,530.11 | 618,271,018.28 |
| 六、净利润 | 1,079,627,854.14 | 4,247,929,628.38 | 3,056,091,951.68 | 2,100,210,564.8 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,079,627,854.14 | 4,247,929,628.38 | 3,056,091,951.68 | 2,100,210,564.8 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 870,825,581.84 | 3,370,561,562.61 | 2,523,293,508.22 | 1,701,967,773.82 |
| 少数股东损益 | 208,802,272.3 | 877,368,065.77 | 532,798,443.46 | 398,242,790.98 |
| 扣除非经常损益后的净利润 | 500,532,364.71 | 2,340,160,476.91 | 1,573,243,380.88 | 960,786,475.56 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.33 | 1.27 | 0.95 | 0.64 |
| (二)稀释每股收益 | 0.33 | 1.27 | 0.95 | 0.64 |
| 八、其他综合收益 | -616,755,016.63 | -675,759,872.93 | -385,229,723.22 | -32,659,264.99 |
| 归属于母公司股东的其他综合收益 | -392,162,147.5 | -456,410,888.81 | -280,830,700.9 | -42,110,038.01 |
| 九、综合收益总额 | 462,872,837.51 | 3,572,169,755.45 | 2,670,862,228.46 | 2,067,551,299.81 |
| 归属于母公司股东的综合收益总额 | 478,663,434.34 | 2,914,150,673.8 | 2,242,462,807.32 | 1,659,857,735.81 |
| 归属于少数股东的综合收益总额 | -15,790,596.83 | 658,019,081.65 | 428,399,421.14 | 407,693,564 |
| 公告日期 | 2026-04-29 | 2026-03-25 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |